Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: European Union Expands Kalydeco’s Approval to Certain CF Patients Ages 1-2 Triple Combo with VX-659 Improves Lung Function in CF Patients with F508del Mutation, Phase 3 Trials Show As Both Patient and Scientist, I’m Putting Nature’s Medicine to the Test European Union Expands Kalydeco’s Approval to Certain CF Patients Ages 1-2 Nov 30, 2018 07:00 am | Patricia Inacio, PhD Kalydeco (ivacaftor) by Vertex Pharmaceuticals has been approved in the European Union for children ages 1-2 with cystic fibrosis (CF) who carry at least one of nine mutations in the CFTR gene — G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R — that prevent the CFTR chloride channel from working properly. “For the first time, EU physicians can now treat the underlying cause of CF earlier than ever, […] The post European Union Expands Kalydeco’s Approval to Certain CF Patients Ages 1-2appeared first on Cystic Fibrosis News Today. Read More Triple Combo with VX-659 Improves Lung Function in CF Patients with F508del Mutation, Phase 3 Trials Show Nov 29, 2018 07:00 am | Jose Marques Lopes, PhD Treatment with a triple combination — the new CFTR corrector VX-659, together with tezacaftor and Kalydeco (ivacaftor) — significantly improved lung function and was well-tolerated by cystic fibrosis (CF) patients, ages 12 and older, with at least one F508del mutation in two Phase 3 studies, according to Vertex Pharmaceuticals. This data support a potential request for approval of this triple […] The post Triple Combo with VX-659 Improves Lung Function in CF Patients with F508del Mutation, Phase 3 Trials Show appeared first on Cystic Fibrosis News Today. Read More As Both Patient and Scientist, I’m Putting Nature’s Medicine to the Test Nov 28, 2018 03:00 pm | Ella Balasa I peered into one of the incubators that stored my petri dishes for 24 hours, anxious to see whether I would discover discoloration and unevenness on the surface, which would have indicated that my experiment produced favorable results. I wanted to see a visual representation of whether manuka honey kills the stubborn Pseudomonas bacterium, which dwells […] The post As Both Patient and Scientist, I’m Putting Nature’s Medicine to the Test appeared first on Cystic Fibrosis News Today. Read More   Recent News Study Reveals How Cystic Fibrosis Affects Young Women’s Sexual Health GEn1E to Explore MUC1-ED to Prevent P. Aeruginosa Infections in CF Cystic Fibrosis Care in Mexico and Brazil: Two Interviews Thanking the Care Teams of Chronic Disease Patients P. aeruginosa Toxin May Be Reason for Single Strains Found in CF Infections, Study Reports